FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003689912> ?p ?o ?g. }

• W2003689912 endingPage "664" @default.
• W2003689912 startingPage "657" @default.
• W2003689912 abstract "Relaxing factors released by the endothelium and their relative contribution to the endothelium-dependent relaxation produced by bradykinin (BK) in comparison with different vasodilator agents were investigated in human omental resistance arteries. BK produced an endothelium-dependent relaxation of arteries pre-contracted with the thromboxane A2 agonist, U46619. The B2 receptor antagonist, Hoe 140 (0.1, 1 and 10 μM), produced a parallel shift to the right of the concentration-response curve to BK with a pA2 of 7.75. Neither the cyclo-oxygenase inhibitor, indomethacin (10 μM) alone, the nitric oxide synthase inhibitor, Nω-nitro-L-arginine methyl ester (L-NAME, 300 μM) alone, the nitric oxide scavenger, oxyhaemoglobin (Hb, 10 μM) alone, nor the combination of L-NAME plus Hb affected the concentration-response curve to BK. Conversely, the combination of indomethacin with either L-NAME or Hb attenuated but did not abolish the BK-induced relaxation. By contrast, the relaxations produced by the Ca2+ ionophore, calcimycin (A23187), and by the inhibitor of sarcoplasmic reticulum Ca2+-ATPase, thapsigargin (THAPS), were abolished in the presence of indomethacin plus L-NAME. Also, the presence of indomethacin plus L-NAME produced contraction of arteries with functional endothelium. The indomethacin plus L-NAME resistant component of BK relaxation was abolished in physiological solution (PSS) containing 40 mM KCl and vice versa. However, in the presence of KCl 40 mM, indomethacin plus L-NAME did not affect the nitric oxide donor, S-N-acetylpenicillamine-induced relaxation. The indomethacin plus L-NAME resistant component of the relaxation to BK was significantly attenuated by the K+ channel blocker tetrabutylammonium (TBA, 1 mM). However, it was not affected by other K+ channel blockers such as apamin (10 μM), 4-aminopyridine (100 μM), glibenclamide (10 μM), tetraethylammonium (10 mM) and charybdotoxin (50 nM). In the presence of indomethacin plus L-NAME, the relaxation produced by BK was not affected by the phospholipase A2 inhibitor, quinacrine (10 μM) or by the inhibitor of cytochrome P450, SKF 525a (10 μM). Another cytochrome P450 inhibitor, clotrimazole (10 μM) which also inhibits K+ channels, inhibited the relaxation to BK. These results show that BK induces endothelium-dependent relaxation in human small omental arteries via multiple mechanisms involving nitric oxide, cyclo-oxygenase derived prostanoid(s) and another factor (probably an endothelium-derived hyperpolarizing factor). They indicate that nitric oxide and cyclo-oxygenase derivative(s) can substitute for each other in producing relaxation and that the third component is not a metabolite of arachidonic acid, formed through the cytochrome P-450 pathway, in these arteries. British Journal of Pharmacology (1997) 121, 657–664; doi:10.1038/sj.bjp.0701169" @default.
• W2003689912 created "2016-06-24" @default.
• W2003689912 creator A5008352425 @default.
• W2003689912 creator A5041886096 @default.
• W2003689912 creator A5056994868 @default.
• W2003689912 creator A5084001156 @default.
• W2003689912 creator A5084952116 @default.
• W2003689912 date "1997-06-01" @default.
• W2003689912 modified "2023-10-18" @default.
• W2003689912 title "Characterization of endothelium-derived relaxing factors released by bradykinin in human resistance arteries" @default.
• W2003689912 cites W1604249157 @default.
• W2003689912 cites W1659953295 @default.
• W2003689912 cites W1975435918 @default.
• W2003689912 cites W1979581487 @default.
• W2003689912 cites W1986658648 @default.
• W2003689912 cites W1995115564 @default.
• W2003689912 cites W1996647976 @default.
• W2003689912 cites W2006006429 @default.
• W2003689912 cites W2007737411 @default.
• W2003689912 cites W2012185701 @default.
• W2003689912 cites W2015161877 @default.
• W2003689912 cites W2036434527 @default.
• W2003689912 cites W2042963094 @default.
• W2003689912 cites W2044038692 @default.
• W2003689912 cites W2048148521 @default.
• W2003689912 cites W2048435005 @default.
• W2003689912 cites W2058472159 @default.
• W2003689912 cites W2077963565 @default.
• W2003689912 cites W2080102822 @default.
• W2003689912 cites W2082392252 @default.
• W2003689912 cites W2095398301 @default.
• W2003689912 cites W2118783941 @default.
• W2003689912 cites W2144486173 @default.
• W2003689912 cites W2152156058 @default.
• W2003689912 cites W2336844186 @default.
• W2003689912 cites W2413612707 @default.
• W2003689912 cites W2432627511 @default.
• W2003689912 cites W4244444868 @default.
• W2003689912 doi "https://doi.org/10.1038/sj.bjp.0701169" @default.
• W2003689912 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1564730" @default.
• W2003689912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9208131" @default.
• W2003689912 hasPublicationYear "1997" @default.
• W2003689912 type Work @default.
• W2003689912 sameAs 2003689912 @default.
• W2003689912 citedByCount "59" @default.
• W2003689912 countsByYear W20036899122013 @default.
• W2003689912 countsByYear W20036899122014 @default.
• W2003689912 countsByYear W20036899122018 @default.
• W2003689912 countsByYear W20036899122021 @default.
• W2003689912 crossrefType "journal-article" @default.
• W2003689912 hasAuthorship W2003689912A5008352425 @default.
• W2003689912 hasAuthorship W2003689912A5041886096 @default.
• W2003689912 hasAuthorship W2003689912A5056994868 @default.
• W2003689912 hasAuthorship W2003689912A5084001156 @default.
• W2003689912 hasAuthorship W2003689912A5084952116 @default.
• W2003689912 hasBestOaLocation W20036899122 @default.
• W2003689912 hasConcept C120770815 @default.
• W2003689912 hasConcept C126322002 @default.
• W2003689912 hasConcept C134018914 @default.
• W2003689912 hasConcept C158617107 @default.
• W2003689912 hasConcept C163415756 @default.
• W2003689912 hasConcept C170493617 @default.
• W2003689912 hasConcept C178790620 @default.
• W2003689912 hasConcept C185592680 @default.
• W2003689912 hasConcept C2776785769 @default.
• W2003689912 hasConcept C2776992346 @default.
• W2003689912 hasConcept C2777146706 @default.
• W2003689912 hasConcept C2777622882 @default.
• W2003689912 hasConcept C2778010969 @default.
• W2003689912 hasConcept C2779591629 @default.
• W2003689912 hasConcept C2781024287 @default.
• W2003689912 hasConcept C519581460 @default.
• W2003689912 hasConcept C55493867 @default.
• W2003689912 hasConcept C71924100 @default.
• W2003689912 hasConcept C89560881 @default.
• W2003689912 hasConcept C98274493 @default.
• W2003689912 hasConceptScore W2003689912C120770815 @default.
• W2003689912 hasConceptScore W2003689912C126322002 @default.
• W2003689912 hasConceptScore W2003689912C134018914 @default.
• W2003689912 hasConceptScore W2003689912C158617107 @default.
• W2003689912 hasConceptScore W2003689912C163415756 @default.
• W2003689912 hasConceptScore W2003689912C170493617 @default.
• W2003689912 hasConceptScore W2003689912C178790620 @default.
• W2003689912 hasConceptScore W2003689912C185592680 @default.
• W2003689912 hasConceptScore W2003689912C2776785769 @default.
• W2003689912 hasConceptScore W2003689912C2776992346 @default.
• W2003689912 hasConceptScore W2003689912C2777146706 @default.
• W2003689912 hasConceptScore W2003689912C2777622882 @default.
• W2003689912 hasConceptScore W2003689912C2778010969 @default.
• W2003689912 hasConceptScore W2003689912C2779591629 @default.
• W2003689912 hasConceptScore W2003689912C2781024287 @default.
• W2003689912 hasConceptScore W2003689912C519581460 @default.
• W2003689912 hasConceptScore W2003689912C55493867 @default.
• W2003689912 hasConceptScore W2003689912C71924100 @default.
• W2003689912 hasConceptScore W2003689912C89560881 @default.
• W2003689912 hasConceptScore W2003689912C98274493 @default.
• W2003689912 hasIssue "4" @default.
• W2003689912 hasLocation W20036899121 @default.

• next